Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details here

Gilead Sciences Inc (GILD) stocks, Expedia Group Inc (EXPE) share price on Friday skyrocketed. Gilead Sciences jumped 8.8 per cent for one of the biggest gains. It reported financial results that easily beat analysts' forecasts, while also raising its earnings forecast for the year. Expedia Group also notched one of the biggest gains, advancing 4.4 per cent after also reporting encouraging financial results. Gilead Sciences Inc and Expedia Group Inc are among the final big batch of companies within the S&P 500 to report mostly strong financial results for the second quarter. Still, many have warned that current tariffs could cut into their profits and operations.

Stocks rose in morning trading on Wall Street Friday, keeping the market on track for its third weekly gain in the last four. The S&P 500 was up 0.7 per cent and sitting just below its record. The benchmark index is on track to wipe out its losses from a slide last week. Dow Jones Industrial Average rose 212 points, or 0.5 per cent. The Nasdaq added 0.8 per cent to the all-time high it set a day earlier. Technology companies, with their hefty stock values, were doing much of the heavy lifting for the market. Nvidia rose 0.9 per cent and Microsoft rose 0.2 per cent.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc. is a leading U.S.-based biopharmaceutical company headquartered in Foster City, California, specializing in antiviral and oncology drugs. Known for major treatments in HIV/AIDS, hepatitis, COVID-19, and cancer, the company is a significant member of the Nasdaq‑100, S&P 100, and S&P 500 indices.

Gilead has since raised its full-year earnings guidance to $7.95–$8.25 per share and product revenue outlook to $28.3–$28.7 billion. Analysts are bullish: Morgan Stanley increased its price target to $143, while TD Cowen raised theirs to $115.

Expedia Group

Expedia Group, Inc., a marquee player in online travel services, operates a diverse portfolio including Expedia.com, Hotels.com, Vrbo, Travelocity, and more. As of August 8, 2025, the stock trades around $193, following a strong Q2 earnings beat that sent shares soaring in pre- and after-hours trading. Analyst reactions are mixed but generally bullish. J.P. Morgan lifted its target to $225 (Neutral); Melius bumped theirs to $210 (Buy); Evercore ISI set a high of $280 (Outperform).

FAQs

Q1. How are Gilead Sciences Inc stocks performing?
A1. Gilead Sciences jumped 8.8 per cent for one of the biggest gains. It reported financial results that easily beat analysts' forecasts, while also raising its earnings forecast for the year.

Q2. How are Expedia Group stocks performing?
A2. Expedia Group also notched one of the biggest gains, advancing 4.4 per cent after also reporting encouraging financial results.